Effects of Leuprorelin on Ovarian Function and Bone Mineral Density in ER Positive Premenopausal Breast Cancer Patients Undergoing Chemotherapy
Objective:To investigate the effect of Leuprorelin on ovarian function and bone mineral density(BMD)of estrogen receptor(ER)positive premenopausal breast cancer patients undergoing chemotherapy.Method:The medical records of 82 ER positive premenopausal breast cancer patients admitted to Fengcheng People's Hospital from January 2020 to August 2022 were retrospectively analyzed,and they were divided into chemotherapy group(n=41)and Leuprorelin group(n=41)according to treatment methods.Patients in chemotherapy group were treated with AC-T adjuvant chemotherapy,and Leuprorelin group was treated with Leuprorelin on the basis of chemotherapy group.The curative effect,ovarian function,BMD and menstruation were compared between the two groups.Result:The total effective rate of Leuprorelin group was higher than that of chemotherapy group(P<0.05).After treatment,serum estradiol(E2)levels in both groups were significantly decreased,and serum luteinizing hormone(LH)and follicle stimulating hormone(FSH)levels were significantly increased(P<0.05);serum LH and FSH levels in Leuprorelin group were significantly higher than those in chemotherapy group,and serum E2 level was significantly lower than that in chemotherapy group(P<0.05).After treatment,BMD levels of left hip and lumbar vertebrae were significantly decreased in both groups(P<0.05);there were no significant differences between the two groups(P>0.05).The amenorrhea time and menstrual normalcy time of Leuprorelin group were shorter than those of chemotherapy group,and the rate of menstrual rehydration was higher than that of chemotherapy group(P<0.05).Conclusion:Leuprorelin can protect the ovarian function in patients with ER positive premenopausal breast cancer undergoing chemotherapy,which can effectively improve the therapeutic effect,but may lead to the decrease of BMD in patients,it is necessary to pay attention to the change of BMD during treatment to reduce the risk of osteoporosis.
Estrogen receptor positivePremenopausal breast cancerChemotherapyLeuprorelinOvarian functionBone minernal density
万方数据
维普
